Patient preference on once-daily oral versus injectable androgen deprivation therapy for Asian patients with advanced prostate cancer.

Ho-Ming Chris WongBernice Cheuk-Sin CheungViolet Wai-Fan YuenJeremy Yuen-Chun TeohPeter Ka-Fung ChiuChi-Fai Ng

Published in: International urology and nephrology (2024)

6-monthly ADT injection was the preferred ADT despite greater cardiovascular risks. Among 1-monthly or daily oral LHRH antagonist, more patients prefer oral option. Convenience factor was highly valued.

Keyphrases

prostate cancer
end stage renal disease
ejection fraction
newly diagnosed
physical activity
chronic kidney disease
prognostic factors
case report
hyaluronic acid
ultrasound guided
risk assessment
climate change